New Delhi: People who have been fully vaccinated by both doses of Covaxin might not be
allowed to travel internationally as the vaccine produced by Bharat Biotech has not been
included in World Health Organization’s (WHO) Emergency Use Listing (EUL) so far, according
to a report. Several nations in Europe are reopening in a bid to boost their travel and tourism
industries and are likely to make regulations for entry of travelers based on recommendations
of their respective health departments or are likely to allow people vaccinated with the shots
manufactured by companies that are on WHO’s EUL list. India’s other vaccine - Covishield -
manufactured by Pune-based Serum Institute of India is on WHO’s EUL. WHO listed the
Pfizer/BioNTech vaccine for emergency use on December 31 last year; two AstraZeneca/Oxford
Covid-19 vaccines on February 15, produced by AstraZeneca-SKBio (Republic of Korea) and
the Serum Institute of India; and the Covid-19 vaccine Ad26.COV2.S developed by Janssen
(Johnson & Johnson) on March 12. The UN body has also approved Moderna’s
Covid-19 vaccine and included China’s Sinopharm COVID-19 vaccine in its EUL. The two other
vaccines used in India’s Covid-19 vaccine drive - Sputnik-V, developed by Russia’s Russian
Direct Investment Fund (RDIF) and the Gamaleya Research Institute of Epidemiology and
Microbiology and Bharat Biotech’s Covaxin are not yet approved by the UN health body. The
European Union (EU), United Kingdom, and Canada also have not included Covaxin in their
approved list of vaccines. The WHO has not made any announcement so far regarding the
inclusion of Covaxin in its EUL. Covaxin, according to WHO’s Guideline Document on “Status of
Covid-19 Vaccines within WHO EUL/PQ evaluation process”, will be reviewed during a meeting
which will be held between May and June 2021. The document also showed that

the Hyderabad-based pharmaceutical company has submitted its expression of interest on April
19.